Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund reduced its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 22.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,883,301 shares of the company’s stock after selling 838,699 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned 1.00% of Taysha Gene Therapies worth $12,888,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Marex Group plc purchased a new position in shares of Taysha Gene Therapies during the second quarter valued at $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies during the second quarter valued at $31,000. Tower Research Capital LLC TRC lifted its stake in Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after acquiring an additional 4,607 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Taysha Gene Therapies by 51.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock worth $43,000 after acquiring an additional 6,350 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Insiders Place Their Bets

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the transaction, the insider owned 936,410 shares of the company’s stock, valued at approximately $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.48% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Bank of America lifted their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Robert W. Baird raised their price target on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. The Goldman Sachs Group boosted their price objective on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $12.77.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $5.54 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. Taysha Gene Therapies, Inc. has a fifty-two week low of $2.54 and a fifty-two week high of $7.30. The stock’s 50-day moving average is $5.97 and its two-hundred day moving average is $5.37. The firm has a market cap of $1.59 billion, a P/E ratio of -14.58 and a beta of 1.17.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Analysts predict that Taysha Gene Therapies, Inc. will post -0.49 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.